| Bioactivity | PCTR1 is a potent monocyte/macrophage agonist, regulating key anti-inflammatory and pro-resolving processes during bacterial infection. PCTR1 is a member of the protectin family of specialized pro-resolving mediators (SPMs)[1]. |
| Invitro | PCTR1 is a peptide-containing lipid mediator. PCTR1 is temporally regulated during self-limited inflammation and promotes the resolution of bacterial infection. PCTR1 significantly decreases prostaglandin (PG)E2 (48%), PGD2 (64%), PGF2α (38%), and thromboxane B2 (40%). PCTR1 increases exudate macrophage levels, accelerates clearance of E. coli infection, decreases local inflammatory mediator production, and promotes resolution[1].PCTR1 is an agonist of human keratinocyte migration and has unique structural features that impart this agonist activity. PCTR1 enhances human keratinocyte migration in a cAMP/PKA-dependent manner. Stimulation of keratinocytes with PCTR1 (10 nM; 15 minutes) significantly elevates levels of cAMP[2]. Cell Viability Assay[2] Cell Line: |
| In Vivo | PCTR1, a lipid mediator, exerts fundamental anti-inflammation and pro-resolution during infection[3].PCTR1 (50 ng/mice) improves the survival rate in an LPS-induced acute inflammatory mouse model[3]. Animal Model: |
| Name | PCTR1 |
| CAS | 1810710-59-8 |
| Formula | C32H47N3O9S |
| Molar Mass | 649.80 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sesquile Ramon, et al. The Protectin PCTR1 Is Produced by Human M2 Macrophages and Enhances Resolution of Infectious Inflammation. Am J Pathol. 2016 Apr;186(4):962-73. [2]. Brian E Sansbury, et al. PCTR1 Enhances Repair and Bacterial Clearance in Skin Wounds. Am J Pathol. 2021 Jun;191(6):1049-1063. [3]. Yong-Jian Liu, et al. PCTR1 ameliorates lipopolysaccharide-induced acute inflammation and multiple organ damage via regulation of linoleic acid metabolism by promoting FADS1/FASDS2/ELOV2 expression and reducing PLA2 expression. Lab Invest. 2020 Jul;100(7) |